NCT00211042View on ClinicalTrials.gov

A Study of Patients With Pure Red Cell Aplasia Associated With Recombinant Human Erythropoietin Treatment

CompletedOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

February 29, 2004

Study Completion Date

December 31, 2006

Conditions

Pure Red-cell Aplasia

Interventions

OTHER

No intervention

This is an observational study. No medication will be given to the participants. Participants will receive standard-of-care treatment from their individual physicians.

Trial Locations (21)

Unknown

Santos

São Paulo

Saskatoon

Darmstadt

Hannoversch Münden

Tvnsberg

Bloemfontein

Karlshamn

Linköping

Stockholm

Trollhättan

N/a N/a

Birmingham

Chelmsford

Edinburgh

London

Manchester

Santander N/A

Telford

Valencia

Westcliff-on-Sea

All Listed Sponsors

lead

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

INDUSTRY

NCT00211042 - A Study of Patients With Pure Red Cell Aplasia Associated With Recombinant Human Erythropoietin Treatment | Biotech Hunter | Biotech Hunter